Ed two models. Model 1 was constructed using variables with P
Ed two models. Model 1 was constructed using variables with P
E 2 cm ESR1-positive and ESR2-low, tumor size >2 cm ESR1-positive or ESR2-low or both, tumor size 2 cm ESR1-positive or ESR2-low or both, tumor size >2 cmaDisease-free survival Number 837 199 638 312 525 410 410 378 459 306 332 175 218 147 181 334 386 HR 95 CI P value 0.001 0.59 0.001 0.19 0.007 0.003 0.43 0.001 0.31 0.001 0.34 0.84 0.005 0.66 0.25 0.82 0.73 0.93 0.94 0.76 1.17 0.79 0.68 0.90 0
Omly assigned patients among treated and untreatedSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 8 ofFigure 1 Metastasis-free survival as a function of dichotomized DC-SCRIPT. Metastasis-free survival is shown as a function of dichotomized DC-SCRIPT in 837 lymph-node negative, primary breast cancer patients after subdividing them accordin
Protein DC-SCRIPT. J Leukoc Biol 2006, 79:1083-1091. 5. Triantis V, Trancikova DE, Looman MW, Hartgers FC, Janssen RA, Adema GJ: Identification and characterization of DC-SCRIPT, a novel dendritic cellexpressed member of the zinc finger family of transcriptional regulators. J Immunol 2006, 176:1081-1089. 6. Lopez-Garcia J, Periyasamy M, Thomas RS, Christian M, Leao M, Jat P, Kindle KB, Heery DM, P
Early breast cancer. The patients described in thisSieuwerts et al. Breast Cancer Research 2010, 12:R103 http://breast-cancer-research.com/content/12/6/RPage 7 ofTable 3 Disease-free survival, metastasis-free survival, and overall survival as a function of continuous DC-SCRIPT in lymph node-negative diseaseAssociation with continuous DC-SCRIPT Cohort Lymph node-negative ESR1 mRNA-negativea ESR1 mR
Antitative polymerase chain reaction cut point for positive versus negative ESR1 and PGR, 0.2 and 0.1, respectively, and for ESR2 at the median level of 0.005 (mRNA levels relative to reference gene set). bInteraction with continuous DC-SCRIPT (P
Ith DFS, MFS, OS, and PFS, respectively. In multivariable analysis, Cox proportional hazards models for DFS, MFS, OS, and PFS were applied to test DCSCRIPT levels added to models with traditional factors. The proportional hazards assumptions were checked with Schoenfeld residuals. The analyses were stratified if necessary. The models for DFS, MFS, and OS for LNN patients who had not received adjuv